The Tempus AI headquarters, located in Chicago’s River North neighborhood, takes up space that would be suitable for a technology company several times its current size. The company is doing something that appears to be genuinely helpful: using AI to assist oncologists in making better treatment decisions by utilizing the molecular and clinical data produced by cancer patients’ diagnostic tests. Tempus now has one of the biggest oncology datasets in private ownership thanks to the diagnostic platform’s ability to handle data at a scale.
The business has alliances with Gilead and Merck. Published data from its ALERT study with Medtronic showed that Tempus AI notifications raised the number of heart valve surgeries that saved lives. However, the company is currently selling close to $48, down more than 53% from a 52-week high of $104.32. As a result, early investors who entered the market close to the peak are sitting on losses that the underlying business hasn’t yet warranted recovering.
Because the operational figures and the headline GAAP numbers tell somewhat different stories, it is important to interpret the Q1 2026 data carefully. Revenue increased 36.1% year over year to $348.1 million, with the Diagnostics sector growing 34.7% and the Data and Applications business growing 40.5%. Due to a greater mix of data-focused products, which have superior economics than the diagnostic volume business, gross profit increased by 43.1% to $222 million, raising gross margin to 63.8%.
The company appears to be making significant strides toward operating profitability on a non-GAAP basis, as seen by the improvement in adjusted EBITDA to a loss of $2.8 million from a loss of $16.2 million a year earlier. The $125.9 million GAAP net loss appears concerning unless you take into consideration $32.3 million in unrealized losses on marketable securities and $56.3 million in stock-based compensation, a non-cash item that appears in GAAP results but doesn’t require cash. Although the GAAP loss figure is slightly inflated by accounting line items rather than operational failure, the operating cash burn is real.
Investors who have been diligently monitoring the stock have been uneasy about the insider selling portion of the TEM story. In the last six months, CEO Eric Lefkofsky sold about 1.19 million shares for an estimated $73.2 million; there were 51 transactions and no purchases. The need for diversification, pre-planned 10b5-1 selling programs, and the fact that founders with huge concentrated ownership must eventually sell some of it are common explanations for the mechanics of executive stock sales.
All of those explanations are valid. The fact that the individual with the most knowledge of the industry has consistently sold at prices much below the 52-week high is not entirely eliminated by them. The words “accelerating demand” and “immense value” used in the earnings call are at odds with the company’s own leadership’s actions in the open market.
The $66–67 analyst consensus price target, which is around 39% above the current share price, is based on the full-year 2026 outlook, which calls for $1.59 to $1.60 billion in revenue at roughly 25% increase and an estimated $65 million in Adjusted EBITDA. With $643.8 million in cash and securities at the end of the first quarter, the corporation can sustain its losses without facing immediate financing concern.
The trajectory from -$2.8 million Adjusted EBITDA in Q1 to +$65 million for the entire year is largely dependent on data licensing income being seasonally better in the second half of the year, which management specifically mentioned during the earnings call as the anticipated trend. That might come to pass. Additionally, it is a forward-looking forecast based on an unfinished product mix.
The market seems to be asking, “What is the fair multiple for a healthcare data and diagnostics company that is growing rapidly, improving margins, and not yet GAAP profitable?” as TEM drops to almost its 52-week low. The Q1 earnings don’t entirely address this concern.
The answer varies significantly based on whether the market for AI diagnostics grows as optimists anticipate and whether Tempus’s data assets generate the kind of pharmaceutical alliance revenue that the Merck and Gilead agreements indicate is feasible. The company is currently operating. Since the 52-week high, skepticism has grown, which is reflected in the stock. In one way or another, those two things will eventually converge.
